Results 241 to 250 of about 198,186 (294)

Improvement in coronary microvascular dysfunction after transcatheter aortic valve implantation leading to positive fractional flow reserve and percutaneous coronary intervention: a case report. [PDF]

Eur Heart J Case Rep
Fujita K, Onishi K, Yoshida A, Matsuzoe H, Nakazawa G.   +4 more
europepmc   +1 more source

Electrocardiographic Features in Transthyretin Cardiac Amyloidosis. [PDF]

Diagnostics (Basel)
Kiuchi S, Hisatake S, Hashimoto H, Murakami Y, Ikeda T.   +4 more
europepmc   +1 more source

Measurement of myocardial extracellular volume fraction and cardiomyocyte diameter before and 6 months after aortic valve replacement in patients with severe aortic stenosis. [PDF]

J Cardiovasc Magn Reson
Sharrack N, Makins A, Biglands JD, Kellman P, Plein S, Buckley DL.   +5 more
europepmc   +1 more source

The impact of metformin on myocardial hypertrophy: an updated systematic review, meta-analysis, and meta-regression of randomized controlled trials. [PDF]

Diabetol Metab Syndr
Azarboo A, Jalali S, Shaker F, Khalaji A, Assempoor R, Javidan A, Mohammadi Y, Bahrami O, Farahmandniya N, Cannavo A.   +9 more
europepmc   +1 more source

A case of hypertrophic cardiomyopathy presenting with high-degree atrioventricular block. [PDF]

Medicine (Baltimore)
Gu Y, Chen F, Zhang C.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Left ventricular hypertrophy

Current Treatment Options in Cardiovascular Medicine, 1999
The presence of left ventricular hypertrophy (LVH) as a treatable entity is of particular importance in patients with primary hypertension. Because LVH is associated with a strong risk of adverse clinical events (eg, heart failure, ischemic events, and cardiovascular death) and because evidence from retrospective studies suggests that regression of LVH,
Ernst E. Van der Wall, Arnoud Van der Laarse, Babette M. Pluim, Albert V. G. Bruschke   +3 more
openaire   +3 more sources